Ovarian Cancer Drugs Market Size, Share & Trends Analysis Report By Therapeutic Class (PARP, PD-L1 Inhibitors , Angiogenesis), By Major Markets (U.S., U.K., Germany, Spain, Italy, France, Japan), And Segment Forecasts, 2016 - 2022
This report can be delivered to the clients within 48 hours
The global ovarian cancer drugs market size is expected to be valued at USD 4.5 billion by 2022, as per a new report by Grand View Research, Inc., expanding at a CAGR of 23.7% during the forecast period. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market.
Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe.
Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies including antibody drug conjugates (ADC) in development are estimated to have a major impact on ovarian cancer treatment spectrum.
Further key findings from the report suggest:
The global ovarian cancer drugs market size is expected to be valued at USD 4.5 billion by 2022, as per a new report by Grand View Research, Inc., expanding at a CAGR of 23.7% during the forecast period. The growth of the market is largely driven by factors such as increased adoption of novel drugs and presence of strong pipeline. Rising incidence of ovarian cancer due to growing geriatric population and unhealthy lifestyles is providing an upthrust to the market.
Ovarian cancer accounts for 3.0% of all malignant tumors among women and 6.0% of all femaledeaths due to cancer. Ovarian cancer accounted for 235,200 new cases and 140,000 deaths worldwide in 2016 with the highest incidence being reported in North America and Europe.
Introduction of non-platinum based PARP inhibitors and VEGF inhibitors in second and third-line settings has changed the treatment regime for ovarian cancer dramatically. Several biologic and small-molecule therapies including antibody drug conjugates (ADC) in development are estimated to have a major impact on ovarian cancer treatment spectrum.
Further key findings from the report suggest:
- EU5 is projected to be the second largest market with more than 10.0% share in 2022, owing to increasing ovarian cancer incidence and approval of PARP inhibitors
- Key players in the industry are focusing on collaborations for development, broader product portfolios, and regional expansion in emerging markets to increase their market share
- Combination regimens and pipeline breakthroughs, specifically those including checkpoint inhibitors such as Roche’s Tecentriq and Pfizer’s Bavencio, are poised to be the upcoming milestones for ovarian cancer treatment
- PARP inhibitors are anticipated to be the fastest growing drug class in the ovarian cancer market through the forecast period. Factors such as continued uptake of approved PARP inhibitors owing to their superior efficacy, long treatment duration, and considerable number of treatment opportunities in first-line advanced settings are likely to propel the growth of the drug class.
- Although angiogenesis inhibitors accounted for the majority of shares in the market in 2016, the drug class is expected to capture a marginal share in 2022 owing to increasing competition from PARP inhibitors and novel pipeline products
- Out of 78 drugs in the pipeline for ovarian cancer, 11 drugs are in Phase III, 29 in Phase II and the remaining in Phase I and pre-clinical trials
- A greater understanding of tumor microenvironment is estimated to occur, which would further drive successful development of new patient-specific therapies through the forecast period
- Late-stage pipeline includes novel drugs such as ImmunoGen’s mirvetuximab soravtansine and Vascular Biogenics’ VBL-111.
CHAPTER 1 RESEARCH METHODOLOGY
1.1. Information Procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1. Disease Primer and Epidemiology
3.1.1. Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S., Japan, EU5)
CHAPTER 4 GLOBAL OVARIAN CANCER DRUGS MARKET OVERVIEW
4.1 Major Therapeutic Classes for Ovarian Cancer
4.2 Market, by Therapeutic Class
4.3 Sales Performance, by Therapeutic Class (2016 - 2022)
4.3.1. PARP Inhibitors
4.3.2. Angiogenesis Inhibitors
4.3.3. PD-L1 Inhibitors
4.4 Market Size and Forecast (2016- 2022)
4.5 Market Size and Forecast, by Seven Major Markets (2016- 2022)
4.5.1 U.S., Sales by Therapeutic Class (2016 - 2022)
4.5.2 U.K., Sales by Therapeutic Class (2016 - 2022)
4.5.3 Germany, Sales by Therapeutic Class (2016 - 2022)
4.5.4 France, Sales by Therapeutic Class (2016 - 2022)
4.5.5 Italy, Sales by Therapeutic Class (2016 - 2022)
4.5.6 Spain, Sales by Therapeutic Class (2016 - 2022)
4.5.7 Japan, Sales by Therapeutic Class (2016 - 2022)
4.6 Market Share Distribution, by Company (2016- 2022)
4.7 Market Dynamics and Brand Strategies
4.8 Patent Expiry Analysis
4.9 Ovarian Cancer Market: Drivers and Restraints
4.9.1 Market Drivers
4.9.2 Market Restraints
4.10. M&A, Deal Landscape (2013-2017 YTD)
4.10.1 Mergers & Acquisitions
4.10.2 Deals Landscape
4.11. Evolution of Biosimilars
4.12. Emerging Markets
4.13. Pricing and Reimbursement Scenario
4.14. Ovarian Cancer Sector SWOT
CHAPTER 5 OVARIAN CANCER DRUGS MARKET: PIPELINE INTELLIGENCE
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Key R&D Trends
5.3 Pipeline Landscape
5.3.1 Late Stage Pipeline and Sales Forecast
5.4 Clinical Profiles of Disruptive Drugs
5.5 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 AstraZeneca
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Forecast Sales Through 2022
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.5 Pipeline Analysis & Overview
6.1.6 SWOT
6.2 Roche/ Genentech
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales Through 2022
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.5 Pipeline Analysis & Overview
6.2.6 SWOT
6.3 Tesaro
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales Through 2022
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 Pipeline Analysis & Overview
6.3.6 SWOT
6.4 Clovis Oncology
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales Through 2022
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.5 Pipeline Analysis & Overview
6.4.6 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 The Winners and Losers
7.2.1 Winners
7.2.2 Losers
7.3 Emerging Companies & Technology Platforms
7.4 The Road Ahead
1.1. Information Procurement
1.2. Information or Data Analysis
1.2.1 Market Formulation & Validation
CHAPTER 2 EXECUTIVE SUMMARY
CHAPTER 3 DISEASE PRIMER AND EPIDEMIOLOGY
3.1. Disease Primer and Epidemiology
3.1.1. Current Prevalence Rate and Incidence Rate for Seven Major Markets (U.S., Japan, EU5)
CHAPTER 4 GLOBAL OVARIAN CANCER DRUGS MARKET OVERVIEW
4.1 Major Therapeutic Classes for Ovarian Cancer
4.2 Market, by Therapeutic Class
4.3 Sales Performance, by Therapeutic Class (2016 - 2022)
4.3.1. PARP Inhibitors
4.3.2. Angiogenesis Inhibitors
4.3.3. PD-L1 Inhibitors
4.4 Market Size and Forecast (2016- 2022)
4.5 Market Size and Forecast, by Seven Major Markets (2016- 2022)
4.5.1 U.S., Sales by Therapeutic Class (2016 - 2022)
4.5.2 U.K., Sales by Therapeutic Class (2016 - 2022)
4.5.3 Germany, Sales by Therapeutic Class (2016 - 2022)
4.5.4 France, Sales by Therapeutic Class (2016 - 2022)
4.5.5 Italy, Sales by Therapeutic Class (2016 - 2022)
4.5.6 Spain, Sales by Therapeutic Class (2016 - 2022)
4.5.7 Japan, Sales by Therapeutic Class (2016 - 2022)
4.6 Market Share Distribution, by Company (2016- 2022)
4.7 Market Dynamics and Brand Strategies
4.8 Patent Expiry Analysis
4.9 Ovarian Cancer Market: Drivers and Restraints
4.9.1 Market Drivers
4.9.2 Market Restraints
4.10. M&A, Deal Landscape (2013-2017 YTD)
4.10.1 Mergers & Acquisitions
4.10.2 Deals Landscape
4.11. Evolution of Biosimilars
4.12. Emerging Markets
4.13. Pricing and Reimbursement Scenario
4.14. Ovarian Cancer Sector SWOT
CHAPTER 5 OVARIAN CANCER DRUGS MARKET: PIPELINE INTELLIGENCE
5.1. Pipeline Landscape
5.1.1 Leading Drugs in Development
5.1.2 Key R&D Trends
5.2 Key R&D Trends
5.3 Pipeline Landscape
5.3.1 Late Stage Pipeline and Sales Forecast
5.4 Clinical Profiles of Disruptive Drugs
5.5 Global Pipeline Forecast
CHAPTER 6 COMPANY PROFILES
6.1 AstraZeneca
6.1.1 Company Overview
6.1.2 Current Product Portfolio
6.1.3 Product Forecast Sales Through 2022
6.1.4 Strategic Initiatives
6.1.4.1 Key Company News Flow
6.1.5 Pipeline Analysis & Overview
6.1.6 SWOT
6.2 Roche/ Genentech
6.2.1 Company Overview
6.2.2 Current Product Portfolio
6.2.3 Product Forecast Sales Through 2022
6.2.4 Strategic Initiatives
6.2.4.1 Key Company News Flow
6.2.5 Pipeline Analysis & Overview
6.2.6 SWOT
6.3 Tesaro
6.3.1 Company Overview
6.3.2 Current Product Portfolio
6.3.3 Product Forecast Sales Through 2022
6.3.4 Strategic Initiatives
6.3.4.1 Key Company News Flow
6.3.5 Pipeline Analysis & Overview
6.3.6 SWOT
6.4 Clovis Oncology
6.4.1 Company Overview
6.4.2 Current Product Portfolio
6.4.3 Product Forecast Sales Through 2022
6.4.4 Strategic Initiatives
6.4.4.1 Key Company News Flow
6.4.5 Pipeline Analysis & Overview
6.4.6 SWOT
CHAPTER 7 MARKET OUTLOOK
7.1 What the Future Holds
7.2 The Winners and Losers
7.2.1 Winners
7.2.2 Losers
7.3 Emerging Companies & Technology Platforms
7.4 The Road Ahead
LIST OF TABLES
TABLE 1 Stages of Ovarian Cancer and Five-Year Survival Rate
TABLE 2 Type of Patients based on Response to Platinum-based Chemotherapy
TABLE 3 Epidemiology of Ovarian Cancer (2016)
TABLE 4 Marketed Drugs for Ovarian Cancer
TABLE 5 Sales by Therapeutic Class, in $ million, 2016 - 2022
TABLE 6 PARP Inhibitors Drug Class, Sales (2016 - 2022)
TABLE 7 Angiogenesis Inhibitors Drug Class, Sales (2016 - 2022)
TABLE 8 PD-L1 Inhibitors Drug Class, Sales (2016 - 2022)
TABLE 9 Sales Performance by Geographic Markets, in $ million, 2016 - 2022
TABLE 10 U.S. Sales by Drug Class (2016 - 2022)
TABLE 11 U.K. Sales by Drug Class (2016 - 2022)
TABLE 12 Germany, Sales by Drug Class (2016 - 2022)
TABLE 13 France, Sales by Drug Class (2016 - 2022)
TABLE 14 Italy, Sales by Drug Class (2016 - 2022)
TABLE 15 Spain, by Drug Class (2016 - 2022)
TABLE 16 Japan, Sales by Drug Class (2016 - 2022)
TABLE 17 Patent Expiry Analysis
TABLE 18 Avastin (bevacizumab) Biosimilars Across Various Indications
TABLE 19 R&D Pipeline Overview – Leading Drugs
TABLE 20 Late Stage Pipeline Analysis
TABLE 21 Bavencio (avelumab)
TABLE 22 VB-111 (ofranergene obadenovec)
TABLE 23 Tecentriq (atezolizumab)
TABLE 24 IMGN853 (mirvetuximab soravtansine)
TABLE 25 Pipeline Forecast
TABLE 26 AstraZeneca Product Forecast Sales (2016 - 2022)
TABLE 27 Roche Product Forecast Sales (2016 - 2022)
TABLE 28 Tesaro Product Forecast Sales (2016 - 2022)
TABLE 29 Clovis Oncology- Product Forecast Sales (2016 - 2022)
TABLE 1 Stages of Ovarian Cancer and Five-Year Survival Rate
TABLE 2 Type of Patients based on Response to Platinum-based Chemotherapy
TABLE 3 Epidemiology of Ovarian Cancer (2016)
TABLE 4 Marketed Drugs for Ovarian Cancer
TABLE 5 Sales by Therapeutic Class, in $ million, 2016 - 2022
TABLE 6 PARP Inhibitors Drug Class, Sales (2016 - 2022)
TABLE 7 Angiogenesis Inhibitors Drug Class, Sales (2016 - 2022)
TABLE 8 PD-L1 Inhibitors Drug Class, Sales (2016 - 2022)
TABLE 9 Sales Performance by Geographic Markets, in $ million, 2016 - 2022
TABLE 10 U.S. Sales by Drug Class (2016 - 2022)
TABLE 11 U.K. Sales by Drug Class (2016 - 2022)
TABLE 12 Germany, Sales by Drug Class (2016 - 2022)
TABLE 13 France, Sales by Drug Class (2016 - 2022)
TABLE 14 Italy, Sales by Drug Class (2016 - 2022)
TABLE 15 Spain, by Drug Class (2016 - 2022)
TABLE 16 Japan, Sales by Drug Class (2016 - 2022)
TABLE 17 Patent Expiry Analysis
TABLE 18 Avastin (bevacizumab) Biosimilars Across Various Indications
TABLE 19 R&D Pipeline Overview – Leading Drugs
TABLE 20 Late Stage Pipeline Analysis
TABLE 21 Bavencio (avelumab)
TABLE 22 VB-111 (ofranergene obadenovec)
TABLE 23 Tecentriq (atezolizumab)
TABLE 24 IMGN853 (mirvetuximab soravtansine)
TABLE 25 Pipeline Forecast
TABLE 26 AstraZeneca Product Forecast Sales (2016 - 2022)
TABLE 27 Roche Product Forecast Sales (2016 - 2022)
TABLE 28 Tesaro Product Forecast Sales (2016 - 2022)
TABLE 29 Clovis Oncology- Product Forecast Sales (2016 - 2022)
LIST OF FIGURES
FIG. 1 Market Research Process
FIG. 2 Information Procurement
FIG. 3 Primary Research Pattern
FIG. 4 Market Research Approaches
FIG. 5 Value Chain based Sizing & Forecasting
FIG. 6 QFD Modelling for Market Share Assessment
FIG. 7 U.S. - Ovarian Cancer Incidence and Mortality Trends
FIG. 8 U.S. - Age Standardized Trends for Ovarian Cancer
FIG. 9 EU5 Ovarian Cancer Incidence Trends
FIG. 10 U.K. - Ovarian Cancer Incidence and Mortality Trends
FIG. 11 Germany - Ovarian Cancer Incidence and Mortality Trends
FIG. 12 Therapeutic Class, Market Share Distribution, 2016 - 2022
FIG. 13 PARP Inhibitors, Market Share Distribution, 2016 - 2022
FIG. 14 Market Size, by Country, 2016 - 2022
FIG. 15 Market Shares Distribution, by Company (2016 - 2022)
FIG. 16 India- Ovarian Cancer Prevalence Trends
FIG. 17 Ovarian Cancer Sector SWOT
FIG. 18 AstraZeneca Ovarian Cancer Sales Forecast
FIG. 19 AstraZeneca SWOT Analysis
FIG. 20 Roche Ovarian Cancer Sales Forecast
FIG. 21 Roche SWOT Analysis
FIG. 22 Tesaro Ovarian Cancer Sales Forecast
FIG. 23 Tesaro SWOT Analysis
FIG. 24 Clovis Oncology Ovarian Cancer Sales Forecast
FIG. 25 Clovis Oncology SWOT Analysis
FIG. 1 Market Research Process
FIG. 2 Information Procurement
FIG. 3 Primary Research Pattern
FIG. 4 Market Research Approaches
FIG. 5 Value Chain based Sizing & Forecasting
FIG. 6 QFD Modelling for Market Share Assessment
FIG. 7 U.S. - Ovarian Cancer Incidence and Mortality Trends
FIG. 8 U.S. - Age Standardized Trends for Ovarian Cancer
FIG. 9 EU5 Ovarian Cancer Incidence Trends
FIG. 10 U.K. - Ovarian Cancer Incidence and Mortality Trends
FIG. 11 Germany - Ovarian Cancer Incidence and Mortality Trends
FIG. 12 Therapeutic Class, Market Share Distribution, 2016 - 2022
FIG. 13 PARP Inhibitors, Market Share Distribution, 2016 - 2022
FIG. 14 Market Size, by Country, 2016 - 2022
FIG. 15 Market Shares Distribution, by Company (2016 - 2022)
FIG. 16 India- Ovarian Cancer Prevalence Trends
FIG. 17 Ovarian Cancer Sector SWOT
FIG. 18 AstraZeneca Ovarian Cancer Sales Forecast
FIG. 19 AstraZeneca SWOT Analysis
FIG. 20 Roche Ovarian Cancer Sales Forecast
FIG. 21 Roche SWOT Analysis
FIG. 22 Tesaro Ovarian Cancer Sales Forecast
FIG. 23 Tesaro SWOT Analysis
FIG. 24 Clovis Oncology Ovarian Cancer Sales Forecast
FIG. 25 Clovis Oncology SWOT Analysis
